TScan Therapeutics, Inc. (TCRX)

Nasdaq: TCRX · Biological Products, (No Diagnostic Substances) · Waltham, MA · filing with the SEC since 2019

Full chart Alerts Compare

Grade4.7

◀ Past 3.9● Present 3.4▶ Future 6.3

1 est.

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

The companyfiscal 2025, as filed

Revenue$10.3M+266.7%

Net income-$130M-1.8%

Earnings per share$-1.00+12.3%

Operating cash flow-$135M-22.1%

Cash$157M-14.3%

Debt$32.5M+1.4%

Shareholders’ equity$123M-48.9%

Shares, diluted129.8M+15.9%

Return on equity-105.4%

The recordfrom its filings

Filings in 202640

Newest filingNov 12 · 10-Q

Annual reportMar 4, 2026

Quarterly reportNov 12, 2026

Next report due10-K by Mar 31

Insider sales, 12 months$0.00

Insider buys, 12 months$0.00

Patents granted0

Filer category<br>Emerging growth company

Trailing twelve months to Sep 2026Revenue $5.2MNet income -$115MCash from operations -$111Mthe four newest filed quarters added

Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.

Revenue and net income by fiscal yearRevenueNet income

202122232425

As filed, in USD. Nothing here is a forecast.

News

Nov 12, 2026 · SEC EDGAR · Form 10-Q

Quarterly report

Open the filing on sec.gov

Nov 12, 2026 · SEC EDGAR · Form 8-K

Results released

Open the filing on sec.gov

Oct 26, 2026 · SEC EDGAR · Form DEF 14A

Proxy statement

Open the filing on sec.gov

Oct 16, 2026 · SEC EDGAR · Form PRE 14A

Preliminary proxy statement

Open the filing on sec.gov

Oct 16, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Oct 2, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Oct 2, 2026 · SEC EDGAR · Form 4

Insider trade report

Open the filing on sec.gov

Sep 30, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

Sep 25, 2026 · SEC EDGAR · Form SCHEDULE 13G

Large holder notice

Open the filing on sec.gov

Sep 11, 2026 · SEC EDGAR · Form 8-K

Current report

Open the filing on sec.gov

An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.

SI brieffrom the record

Core business

TScan Therapeutics, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Waltham, MA.

Newest on the record

Quarterly report on Nov 12. Before it, current report on Nov 12.

What is due next

The 10-K for the period to Dec 31, 2026, due by Mar 31, 2027.

About TCRX

TScan Therapeutics, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Waltham, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $10 million and a loss of $130 million (its filed statements).

IndustryBiological Products, (No Diagnostic Substances)

HeadquartersWaltham, MA

Business modelPre-revenue company

ExchangeNasdaq

Filing since2019

Fiscal year endsDec 31

SEC number (CIK)1783328

Peers on fileSLDB, DBVT, ENGN, CMPX

Who runs it

Financial performance

In fiscal 2025 TScan Therapeutics’s revenue was $10.32 million, up 266.7% from $2.82 million the year before. It made a net loss of $129.8 million.

Annual report, filed Mar 4, 2026.

Financial statements

The grade

TScan Therapeutics grades 4.7 of 10 against its own industry, the 159 companies in Biological Products, (No Diagnostic Substances). Eight of the nine metrics are read as filed and one is an SI estimate, each with its reasoning.

◀ Past3.9

● Present3.4

▶ Future6.3

How the grade is made

Forecast

Every forecast is registered before the outcome, with the rule that settles it. A miss stays on the page.

Company forecasts

SI Assistanton TCRX · research, not advice